-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Digital and Intelligent Transformation: Standards Lead the Way | Keyuan Pharmaceutical Joins the Development of the "Guidelines for Digital Transformation in Pharmaceutical Companies"!
Publish Time:
2024-09-02
Recently, the China United Nations Procurement Promotion Association released the group standard T/UNP 178—2024, "Guidelines for Digital Transformation in Pharmaceutical Companies," marking a significant step forward for China's pharmaceutical enterprises in their digital transformation journey.
Recently, the China United Nations Procurement Promotion Association released the group standard T/UNP 178—2024, the "Guidelines for Digital Transformation in Pharmaceutical Enterprises," marking a significant step forward for China's pharmaceutical companies in their digital transformation journey. Shandong Keyuan Pharmaceutical Co., Ltd. (stock code: 301281.SZ), as one of the key drafting units, actively participated in the development of this standard.
The "Guidelines for Digital Transformation in Pharmaceutical Enterprises" comprehensively cover various aspects, including transformation planning, resource support, operational implementation, evaluation and inspection, as well as continuous improvement and enhancement. By clearly defining the goals, pathways, and specific measures for digital transformation, these guidelines help enterprises establish a robust, science-based digital transformation framework, enabling them to reinvent and optimize business processes, ultimately strengthening their core competitiveness and accelerating their ability to respond swiftly to market demands.
It is reported that the group standard "Guidelines for Digital Transformation in Pharmaceutical Companies" was officially released on August 23, 2024, and will come into full effect on November 23, 2024. Adhering to the principles of openness, fairness, transparency, consensus-building, and the promotion of trade and exchange, this standard aims to guide pharmaceutical companies in smoothly advancing their digital transformation, thereby enhancing overall operational efficiency and market competitiveness.
As a leading enterprise in China's niche segment of chemical APIs, Keyuan Pharmaceutical has consistently driven high-quality development through technological innovation and industrial upgrading. This participation in drafting the "Guidelines for Digital Transformation in Pharmaceutical Companies" not only highlights the company's deep expertise in digital transformation but also underscores its prominent position and influence within the industry.
In the midst of profound transformations sweeping across the global health industry, the digital transformation of the greater healthcare sector is not merely an upgrade—it’s a revolution, a leap forward that will undoubtedly become the core driving force behind the industry’s future growth.
In the wave of digital transformation in the pharmaceutical industry, Keyuan Pharmaceutical has proactively responded to national policies with its keen industry sensitivity and innovative capabilities. Focusing on smart factories, digitized workshops, and unmanned production lines as key growth areas, the company has successfully integrated enterprise resource planning, product lifecycle management, and supply chain management systems—accelerating its own digital and intelligent transformation and upgrading.
Thanks to its outstanding innovation capabilities and remarkable achievements in digital and intelligent transformation, Keyuan Pharmaceutical is proudly listed on the "2024 Shandong Province Benchmark Enterprise List for Intelligent Transformation of the Chemical Industry"!
During the development of the "Guidelines for Digital Transformation in Pharmaceutical Companies" standard, Keyuan Pharmaceutical leveraged its own practical experience to offer numerous valuable insights and recommendations, which were ultimately adopted and integrated into the standard, providing crucial reference and guidance for pharmaceutical companies undergoing digital transformation.
Keyuan Pharmaceutical stated that participating in the development of this standard is a concrete action taken by the company to actively respond to national policies and drive industry growth. Moving forward, the company will continue to uphold its core philosophy of "Healthy China, Heartfelt Commitment," steadily increasing its investments and efforts in digital transformation—setting an example and contributing significantly to the pharmaceutical industry's transformation, upgrading, and high-quality development.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline